Details

Autor(en) / Beteiligte

• McDonald, Gabrielle
• Chubukov, Victor
• Coco, John
• Truskowski, Kevin
• Narayanaswamy, Rohini
• Choe, Sung
• Steadman, Mya
• Artin, Erin
• Padyana, Anil K
• Jin, Lei
• Ronseaux, Sebastien
• Locuson, Charles
• Fan, Zi-Peng
• Erdmann, Tabea
• Mann, Alan
• Hayes, Sebastian
• Fletcher, Mark
• Nellore, Kavitha
• Rao, Siva Sanjeeva
• Subramanya, Hosahalli
• Reddy, K Satish
• Panigrahi, Sunil K
• Antony, Thomas
• Gopinath, Sreevalsam
• Sui, Zhihua
• Nagaraja, Nelamangala
• Dang, Lenny
• Lenz, Georg
• Hurov, Jonathan
• Biller, Scott A
• Murtie, Josh
• Marks, Kevin M
• Ulanet, Danielle B

Titel

Selective Vulnerability to Pyrimidine Starvation in Hematologic Malignancies Revealed by AG-636, a Novel Clinical-Stage Inhibitor of Dihydroorotate Dehydrogenase

Ist Teil von

• Molecular cancer therapeutics, 2020-12, Vol.19 (12), p.2502-2515

Ort / Verlag

United States

Erscheinungsjahr

2020

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• Agents targeting metabolic pathways form the backbone of standard oncology treatments, though a better understanding of differential metabolic dependencies could instruct more rationale-based therapeutic approaches. We performed a chemical biology screen that revealed a strong enrichment in sensitivity to a novel dihydroorotate dehydrogenase (DHODH) inhibitor, AG-636, in cancer cell lines of hematologic versus solid tumor origin. Differential AG-636 activity translated to the setting, with complete tumor regression observed in a lymphoma model. Dissection of the relationship between uridine availability and response to AG-636 revealed a divergent ability of lymphoma and solid tumor cell lines to survive and grow in the setting of depleted extracellular uridine and DHODH inhibition. Metabolic characterization paired with unbiased functional genomic and proteomic screens pointed to adaptive mechanisms to cope with nucleotide stress as contributing to response to AG-636. These findings support targeting of DHODH in lymphoma and other hematologic malignancies and suggest combination strategies aimed at interfering with DNA-damage response pathways.